BioEquity Europe will give biotech, pharma and medtech start-ups the opportunity to shine and potentially attract global investment.
BioEquity Europe is an international showcase where financial dealmakers and biopharma execs meet rising biotech startups.
While Covid-19 restrictions prevent the event from taking place last year, soon to arrive in Ireland for the first time, the 2021 conference is set to continue online next week (17 to 19 May 2021).
The event will host strategic panels in the biotech sector and give more than 130 companies the opportunity to meet international VCs.
Among the companies are six spin-outs from Trinity College Dublin (TCD) and Royal College of Surgeons in Ireland (RSCI) that promote a variety of solutions to not meet clinical needs in disease areas. such as autoimmunity, glaucoma and sepsis.
Five of these six spin-outs will participate in the BioEquity Europe conference’s first dedicated track for spin-outs from academic institutions, while the sixth start will be shown on a pre-seed track in event.
Eric Pierce, publisher of BioCentury which organizes BioEquity Europe, said he was extremely impressed with the caliber of spin-outs from TCD and RCSI.
“We’re creating BioEquity history because it’s the first time in 21 years of running this event that we have a dedicated track for academic rounds, and we look forward to making rotation sessions that it’s part of the future BioEquity program. “
Spin-outs from life sciences research at RCSI and TCD will be a key deliverable by the knowledge transfer agreement at RCSI-Trinity, a partnership supported by Knowledge Transfer Ireland and Enterprise Ireland.
Dr Aoife Gallagher, head of innovation at RCSI said: “What is extremely inspiring is the depth and scale created by our two institutes working together, allowing us to showcase our portfolio of spin-outs. to an international investor audience. ”
TCD rotation Azadyne aims to deliver improved medicines for patients with autoimmune diseases, including multiple sclerosis.
Its novel approach focuses on an unexplored pathway in the body and is based on research conducted at TCD by associate professor of biochemistry Vincent Kelly, professor of synthetic chemistry Stephen Connon and assistant professor of chemistry John Michael Southern.
In 2019, the start rise € 1.75m in a round of investments led by NCL Technology Ventures and new private investors.
Exhaura is an ophthalmology gene therapy company with an initial focus on glaucoma. The modification that supports the Exhaura pipeline was developed at TCD’s School of Genetics and includes innovative cost-effective intraocular pressure-lowering and neuroprotective genotherapy products.
The company is supported by a deeply experienced team with a track record of financing, developing and manufacturing gen therapy products. It is among five TCD companies honored with 2019 Trinity Innovation Awards.
Founded by Dr. Julie Kelly, Neuropath is committed to developing the translation of a promising lead compound as a potential drug for neurodegenerative diseases, such as motor neuron disease.
Kelly discovered this compound through his research on TCD on the effects of the central nervous system and the therapeutic potential of the thyrotropin -releasing hormone. The initial goal of Neuropath is to advance this TRH-based lead compound from the laboratory to the early stages of human clinical trials.
RCSI rotation Oncolize is developing injectable drug depots for better tumor treatment based on ChemoGel, a thermo-responsive gel drug delivery platform for local and site-specific treatment of solid tumors.
Oncolize products can be delivered through regular procedures and can enable localized and controlled release of both approved drugs and novel drugs within solid tumors. The start-up aims to increase overall survival time for patients suffering from difficult to treat and aggressive solid tumors such as pancreatic cancer, liver cancer and brain and endocrine cancers.
Inthelia Therapeutics is a clinical stage pharmaceutical company that revolved around RCSI. It aims to develop personalized therapeutic approaches to support recovery from or prevent death due to pathogen-induced endothelial dysfunction and infections, including sepsis and septic shock.
The company is raising € 22m to establish a team and fund the completion of a Phase 2a clinical trial on sepsis patients. The objectives of the test are to identify the optimal dose and confirm safety.
TCD rotation Vertigenius will present on a pre-seed track at BioEquity Europe. The company has developed medical device technology for the treatment of dizziness, vertigo and imbalance.
Vertigenius offers a clinician portal, a wearable head sensor to track head movements, and a handy patient app. The company is currently testing its platform in a clinical study at a university teaching hospital. The company featured last year Showcase of Big Ideas in Enterprise Ireland.
Do you want stories like this and more directed to your inbox? Sign up for Tech Trends, Weekly melting news about must-know news in Silicon Republic.